HUP0001237A3 - Methods for treating vascular disorders - Google Patents

Methods for treating vascular disorders

Info

Publication number
HUP0001237A3
HUP0001237A3 HU0001237A HUP0001237A HUP0001237A3 HU P0001237 A3 HUP0001237 A3 HU P0001237A3 HU 0001237 A HU0001237 A HU 0001237A HU P0001237 A HUP0001237 A HU P0001237A HU P0001237 A3 HUP0001237 A3 HU P0001237A3
Authority
HU
Hungary
Prior art keywords
methods
vascular disorders
treating vascular
treating
disorders
Prior art date
Application number
HU0001237A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of HUP0001237A2 publication Critical patent/HUP0001237A2/hu
Publication of HUP0001237A3 publication Critical patent/HUP0001237A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Surgery (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HU0001237A 1997-10-20 1998-03-24 Methods for treating vascular disorders HUP0001237A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6254997P 1997-10-20 1997-10-20
US6476597P 1997-11-07 1997-11-07

Publications (2)

Publication Number Publication Date
HUP0001237A2 HUP0001237A2 (hu) 2000-08-28
HUP0001237A3 true HUP0001237A3 (en) 2002-01-28

Family

ID=26742406

Family Applications (2)

Application Number Title Priority Date Filing Date
HU0001237A HUP0001237A3 (en) 1997-10-20 1998-03-24 Methods for treating vascular disorders
HU0100025A HU224901B1 (en) 1997-10-20 1998-10-14 Methods for treating hypercoagulable states or acquired protein c deficiency

Family Applications After (1)

Application Number Title Priority Date Filing Date
HU0100025A HU224901B1 (en) 1997-10-20 1998-10-14 Methods for treating hypercoagulable states or acquired protein c deficiency

Country Status (28)

Country Link
US (7) US6037322A (hu)
EP (2) EP0913156B1 (hu)
JP (2) JP3805981B2 (hu)
KR (1) KR100798174B1 (hu)
CN (1) CN1276726A (hu)
AT (1) ATE292979T1 (hu)
AU (1) AU748417B2 (hu)
BR (1) BR9812965A (hu)
CA (1) CA2306983A1 (hu)
DE (1) DE69829721T2 (hu)
DK (1) DK0913156T3 (hu)
EA (1) EA002496B1 (hu)
ES (1) ES2239382T3 (hu)
HK (1) HK1020529A1 (hu)
HU (2) HUP0001237A3 (hu)
ID (1) ID24901A (hu)
IL (2) IL135712A0 (hu)
MY (1) MY117655A (hu)
NO (1) NO20002005L (hu)
NZ (1) NZ504026A (hu)
PL (1) PL200515B1 (hu)
PT (1) PT913156E (hu)
SI (1) SI0913156T1 (hu)
TR (1) TR200001059T2 (hu)
TW (1) TWI225404B (hu)
UA (1) UA72194C2 (hu)
WO (1) WO1999020293A1 (hu)
ZA (1) ZA989385B (hu)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID22933A (id) 1997-04-28 1999-12-16 Lilly Co Eli Fomulasi protien c terakivasi
US6630137B1 (en) 1997-04-28 2003-10-07 Eli Lilly And Company Activated protein C formulations
HUP0001237A3 (en) * 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
US7175679B2 (en) * 2001-03-29 2007-02-13 Biotempt B.V. Oligopeptide treatment of NF-κB mediated inflammation
US8680059B2 (en) 1998-05-20 2014-03-25 Biotempt B.V. Oligopeptide acetate and formulations thereof
US20040202645A1 (en) * 2003-04-08 2004-10-14 Khan Nisar Ahmed Administration of gene-regulatory peptides
US20050227925A1 (en) * 2004-04-08 2005-10-13 Robbert Benner Compositions capable of reducing elevated blood urea concentration
US20030220258A1 (en) * 2001-12-21 2003-11-27 Robbert Benner Treatment of ischemic events
US6921751B1 (en) 1998-05-20 2005-07-26 Erasmus Universiteit Rotterdam Immunoregulator
US6844315B2 (en) * 1998-05-20 2005-01-18 Erasmus Universiteit Rotterdam Immunoregulator
EP1138692A1 (en) * 2000-03-29 2001-10-04 Erasmus Universiteit Rotterdam Fragments of human chorionic gonadotropin (hcg) as immunoregulator
US20040199099A1 (en) * 1998-07-10 2004-10-07 Matson James R Hemofiltration systems, methods and devices used to treat inflammatory mediator related disease
US6287516B1 (en) 1998-07-10 2001-09-11 Immunocept, L.L.C. Hemofiltration systems, methods, and devices used to treat inflammatory mediator related disease
IL142248A0 (en) 1998-10-22 2002-03-10 Lilly Co Eli Methods for treating sepsis
CA2351067A1 (en) * 1998-11-13 2000-05-25 Eli Lilly And Company Method of treating heparin-induced thrombocytopenia
CN1326357A (zh) * 1998-11-23 2001-12-12 伊莱利利公司 治疗镰刀形红细胞贫血病及地中海贫血病的方法
AU2001238034A1 (en) * 2000-02-04 2001-08-14 The Scripps Research Institute Neuroprotective, antithrombotic and anti-inflammatory uses of activated protein c (apc)
US7291122B2 (en) * 2000-03-24 2007-11-06 Immunocept, L.L.C. Hemofiltration methods for treatment of diseases in a mammal
US6736972B1 (en) 2000-03-24 2004-05-18 Immunocept, L.L.C. Method and system for providing therapeutic agents with hemofiltration for reducing inflammatory mediator related diseases
US8535258B2 (en) * 2000-03-24 2013-09-17 Immunocept, L.L.C. Hemofiltration methods for treatment of diseases in a mammal
US7204981B2 (en) * 2000-03-28 2007-04-17 Eli Lilly And Company Methods of treating diseases with activated protein C
AU2001245319A1 (en) * 2000-03-28 2001-10-08 Eli Lilly And Company Methods of treating diseases with activated protein c
US7358330B2 (en) 2001-03-29 2008-04-15 Biotempt B.V. Immunoregulatory compositions
EP1300418A1 (en) * 2001-10-04 2003-04-09 Erasmus Universiteit Rotterdam Gene regulation by oligopeptides
USRE43279E1 (en) 2000-03-29 2012-03-27 Biotemp B.V. Compositions capable of reducing elevated blood urea concentration
US20050037430A1 (en) * 2000-03-29 2005-02-17 Biotempt B.V. Methods and uses for protein breakdown products
US7576174B2 (en) * 2000-03-29 2009-08-18 Biotempt B.V. Compositions capable of reducing elevated blood urea concentration
US6787040B2 (en) * 2000-05-16 2004-09-07 Immunocept, L.L.C. Method and system for colloid exchange therapy
US8597516B2 (en) * 2000-05-16 2013-12-03 Immunocept, L.L.C. Methods and systems for colloid exchange therapy
US7087578B2 (en) * 2000-05-24 2006-08-08 Eli Lilly And Company Formulations and methods for treating hypercoagulable states
WO2002024215A2 (en) * 2000-09-18 2002-03-28 Eli Lilly And Company Method for using activated protein c for the treatment of coagulation-associated disorders
HUP0303199A2 (hu) 2001-02-19 2003-12-29 Merck Patent Gmbh Eljárás T-sejt-epitópok azonosítására és csökkentett immunogenitású molekulák előállítására
US20040198652A1 (en) * 2001-04-24 2004-10-07 Carter J. Paul Methods and compositions for preventing and treating septic shock and endotoxemia
ES2384099T3 (es) 2001-06-13 2012-06-29 The University Of Sydney Proteína C para cicatrización de heridas
JP2004535461A (ja) * 2001-07-19 2004-11-25 ディーエムアイ バイオサイエンシズ インコーポレイテッド プロテインｃの不活性化を抑制するための銅キレート剤の使用
US20030220259A1 (en) * 2001-12-21 2003-11-27 Robbert Benner Treatment of neurological disorders
WO2003055442A2 (en) 2001-10-15 2003-07-10 Chiron Corporation Treatment of sepsis by low dose administration of tissue factor pathway inhibitor (tfpi)
US20030220260A1 (en) * 2001-12-21 2003-11-27 Khan Nisar Ahmed Peptide compositions
US20040013661A1 (en) * 2001-12-21 2004-01-22 Gert Wensvoort Stratification
US7560433B2 (en) * 2001-12-21 2009-07-14 Biotempt B.V. Treatment of multiple sclerosis (MS)
US20030220257A1 (en) * 2001-12-21 2003-11-27 Robbert Benner Treatment of trauma
US20030220261A1 (en) * 2001-12-21 2003-11-27 Khan Nisar Ahmed Treatment of iatrogenic disease
US7786084B2 (en) 2001-12-21 2010-08-31 Biotempt B.V. Treatment of burns
US7501391B2 (en) * 2001-12-21 2009-03-10 Biotempt B.V. Treatment of transplant survival
US20030224995A1 (en) * 2001-12-21 2003-12-04 Khan Nisar Ahmed Treatment of burns
US20080318871A1 (en) * 2001-12-21 2008-12-25 Khan Nisar A Treatment of neurological disorders
WO2003075834A2 (en) * 2002-03-08 2003-09-18 Eli Lilly And Company Activated protein c formulations
TW200407335A (en) * 2002-07-22 2004-05-16 Chugai Pharmaceutical Co Ltd Non-neutralizing antibody to inhibit the inactivation of activated protein C
CA2495459C (en) * 2002-08-13 2009-10-27 Arbios Technologies Inc. Selective plasma exchange therapy
WO2004056309A2 (en) 2002-12-05 2004-07-08 Socratech L.L.C. Neuroprotective activity of activated protein c is independent of its anticoagulant activity
US20060167230A1 (en) * 2003-01-20 2006-07-27 Takaki Koga Anti-pci neutralizing antibody
US20070142272A1 (en) * 2003-01-24 2007-06-21 Zlokovic Berislav V Neuroprotective activity of activated protein c independent of its anticoagulant activity
US7517529B2 (en) * 2003-04-08 2009-04-14 Biotempt B.V. Treatment of type I diabetes
CA2524534C (en) 2003-05-15 2012-12-11 Sek Chung Fung Methods and compositions for the prevention and treatment of sepsis
WO2005007820A2 (en) 2003-07-08 2005-01-27 The Scripps Research Institute Activated protein c variants with normal cytoprotective activity but reduced anticoagulant activity
US9192657B2 (en) 2003-07-08 2015-11-24 The Scripps Research Institute Activated protein C variants with normal cytoprotective activity but reduced anticoagulant activity
US20090227669A1 (en) * 2004-01-23 2009-09-10 The University Of Toledo Compositions and Methods for Perioperative Bladder Instillation
EP1729791A2 (en) * 2004-03-17 2006-12-13 Chiron Corporation Treatment of severe community-acquired pneumonia by admistration of tissue factor pathway inhibitor (tfpi)
CA2566411A1 (en) * 2004-05-11 2005-11-24 Heptest Laboratories, Inc. Compositions, kit and one-step method for monitoring compounds having anti-factor xa and/or anti factor iia activities
WO2006014839A2 (en) * 2004-07-23 2006-02-09 The University Of Rochester Activated protein c inhibits undesirable effects of plasminogen activator in the brain
WO2006124770A2 (en) * 2005-05-13 2006-11-23 The Feinstein Institute For Medical Research Treatment of sepsis and inflammation with alpha2a adrenergic antagonists
CA2612597C (en) * 2005-06-24 2015-03-31 Drugrecure Aps Airway administration of activated protein c in inflammatory conditions affecting the respiratory tract
SG163567A1 (en) 2005-07-05 2010-08-30 Biotempt Bv Treatment of tumors
EP1864692A1 (en) 2006-06-07 2007-12-12 Biotempt B.V. Use of peptides for the control of radiation injury
US7785857B2 (en) * 2006-08-31 2010-08-31 Saint Louis University Protein C variant
GR1005700B (el) * 2006-09-01 2007-10-22 (40%) ����� �������� Τροπος αντιμετωπισης της 1ης φασης του εγκαυματοσσε μη σηπτικους ασθενεις με συνεχη ενδοφλεβια χορηγηση ενεργοποιημενης πρωτεινης-c για 48 ωρες με στοχο τη μειωση της τελικης εγκαυματικης βλαβης καιαυξηση της ταχυτητας επουλωσης κατα τα πρωτα επτα μετεγκαυματικα 24ωρα
CA2668187A1 (en) * 2006-10-31 2008-06-19 The Scripps Research Institute Dosing regimen of activated protein c and variants having reduced anticoagulant activity
RU2445365C1 (ru) * 2010-11-03 2012-03-20 Общество с ограниченной ответственностью "Инновационный Центр "Новые Технологии и Материалы" (ООО "ИЦ Новтехмат") Штамм гибридных культивируемых клеток mus musculus - продуцент моноклональных антител, специфичных к протеину с человека (варианты)
RU2490722C1 (ru) * 2012-04-24 2013-08-20 Федеральное государственное бюджетное учреждение науки Институт химической биологии и фундаментальной медицины Сибирского отделения Российской академии наук (ИХБФМ СО РАН) Способ восстановления кровотока в регионе тромбированной вены в эксперименте
EP2869833B1 (en) 2012-07-04 2018-04-04 ZZ Biotech LLC. Activated protein c for use in the treatment of inflammatory skin disorders
WO2015157791A1 (en) 2014-04-16 2015-10-22 The University Of Sydney Treatment of abnormal cutaneous scarring
JP7277484B2 (ja) 2018-06-15 2023-05-19 エービー サンドビック マテリアルズ テクノロジー 二相ステンレス鋼ストリップおよびそれを製造するための方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US5516650A (en) * 1985-06-27 1996-05-14 Zymogenetics, Inc. Production of activated protein C
US5084274A (en) * 1987-11-17 1992-01-28 Scripps Clinic And Research Foundation Inhibition of arterial thrombotic occlusion or thromboembolism
US4992373A (en) * 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
US5009889A (en) * 1987-12-31 1991-04-23 Oklahoma Medical Research Foundation Treatment of dysfunctional vascular endothelium using activated protein C
GB8819607D0 (en) * 1988-08-17 1988-09-21 Wellcome Found Novel combination
US4981952A (en) * 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
US5254532A (en) * 1989-06-26 1993-10-19 Immuno Aktiengesellschaft Fur Chemisch-Medizinische Produkte Preparation for treating and preventing thromboses and thromboembolic complications, use of such a preparation and a method of producing the same
IL97312A (en) * 1990-02-23 1999-01-26 Lilly Co Eli A method of generating a polypeptide in an eukaryotic vector AND recombinant surrogate cell containing an enhanced transcriptional control unit based on the primary late adenovirus coefficient
AT402262B (de) * 1991-06-20 1997-03-25 Immuno Ag Arzneimittel enthaltend aktiviertes protein c
MY110664A (en) * 1992-05-21 1999-01-30 Lilly Co Eli Protein c derivatives
JP3434326B2 (ja) * 1992-08-25 2003-08-04 財団法人化学及血清療法研究所 成人呼吸窮迫症候群（ａｒｄｓ）予防、治療剤
JP2825739B2 (ja) * 1993-09-20 1998-11-18 帝人株式会社 急性肝不全治療剤
JP3802104B2 (ja) * 1995-05-31 2006-07-26 財団法人化学及血清療法研究所 脊髄損傷に伴う神経障害の予防・治療剤
WO1997020043A1 (en) * 1995-11-30 1997-06-05 Zymogenetics, Inc. Protein c production in transgenic animals
ID22933A (id) * 1997-04-28 1999-12-16 Lilly Co Eli Fomulasi protien c terakivasi
HUP0001237A3 (en) * 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders

Also Published As

Publication number Publication date
TWI225404B (en) 2004-12-21
ZA989385B (en) 2000-04-14
ID24901A (id) 2000-08-31
CA2306983A1 (en) 1999-04-29
US6426071B2 (en) 2002-07-30
HUP0100025A3 (en) 2003-08-28
DK0913156T3 (da) 2005-06-27
US6156734A (en) 2000-12-05
EP1449537A3 (en) 2005-09-21
IL135712A (en) 2010-12-30
DE69829721D1 (de) 2005-05-19
US20010036456A1 (en) 2001-11-01
US6268337B1 (en) 2001-07-31
HUP0001237A2 (hu) 2000-08-28
HU224901B1 (en) 2006-04-28
WO1999020293A1 (en) 1999-04-29
US6268344B1 (en) 2001-07-31
US6489296B1 (en) 2002-12-03
PT913156E (pt) 2005-08-31
JP3805981B2 (ja) 2006-08-09
JP2005097313A (ja) 2005-04-14
EA200000445A1 (ru) 2000-10-30
US6037322A (en) 2000-03-14
PL200515B1 (pl) 2009-01-30
AU9804098A (en) 1999-05-10
EP0913156B1 (en) 2005-04-13
IL135712A0 (en) 2001-05-20
EA002496B1 (ru) 2002-06-27
CN1276726A (zh) 2000-12-13
MY117655A (en) 2004-07-31
BR9812965A (pt) 2001-03-20
TR200001059T2 (tr) 2000-10-23
DE69829721T2 (de) 2006-02-09
US6008199A (en) 1999-12-28
SI0913156T1 (en) 2005-10-31
JP2001520199A (ja) 2001-10-30
ES2239382T3 (es) 2005-09-16
PL340096A1 (en) 2001-01-15
KR100798174B1 (ko) 2008-01-24
KR20010031217A (ko) 2001-04-16
EP1449537A2 (en) 2004-08-25
ATE292979T1 (de) 2005-04-15
HUP0100025A2 (hu) 2001-05-28
NZ504026A (en) 2002-12-20
UA72194C2 (en) 2005-02-15
HK1020529A1 (en) 2000-05-12
AU748417B2 (en) 2002-06-06
NO20002005D0 (no) 2000-04-17
NO20002005L (no) 2000-05-16
EP0913156A1 (en) 1999-05-06

Similar Documents

Publication Publication Date Title
HUP0001237A3 (en) Methods for treating vascular disorders
HUP0003964A2 (en) Methods for treating thrombotic disorders
PL336290A1 (en) Sulphonamides for treating endothelin-involving disorders
IL126203A0 (en) Method for treating pain
EP0906104A4 (en) PAIN TREATMENT PROCESS
AU9035498A (en) Method for treating pain
IL134289A0 (en) Methods for treating neurological deficits
GB9605828D0 (en) Treatment method
HK1026596A1 (en) Method for determining data for treating the cornea
IL126064A0 (en) Method for treating pain
GB9719161D0 (en) New therapeutic method
PL332821A1 (en) Pyrazolydinones for treating potency disorders
AU9034798A (en) Method for treating pain
GB9615767D0 (en) Novel treatment
GB9714841D0 (en) Treatment method
ZA977867B (en) Method of treatment.
GB9608657D0 (en) Novel treatment
ZA982489B (en) Methods for treating vascular disorders.
ZA987960B (en) Methods for treating ocular diseases
GB9703102D0 (en) Treatment method
GB9719176D0 (en) New therapeutic method
GB9719189D0 (en) New therapeutic method
GB9612752D0 (en) Novel treatment
GB9614743D0 (en) Treatment method
GB9614741D0 (en) Treatment method